RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine

Oncogene

Volumn 32, Issue 40, 2013, Pages 4789-4797

  Saunders, P O ^a   Weiss, J ^a   Welschinger, R ^a   Baraz, R ^a   Bradstock, K F ^a   Bendall, L J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

acute lymphoblastic leukemia; checkpoint regulation; chemotherapy; mitosis; mTOR inhibitors; RAD001

Indexed keywords

CELL CYCLE PROTEIN 20; CYCLIN D1; EVEROLIMUS; KI 67 ANTIGEN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA CONTENT; DNA DAMAGE; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MICROTUBULE; MITOSIS; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED NOD; MICE, SCID; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIROLIMUS; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84885182576     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.498     Document Type: Article

References (38)

1. Silverman LB, Stevenson KE, O?Brien JE, Asselin BL, Barr RD, Clavell L et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2009; 24: 320-334.
2. Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
3. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46: 64-75.
4. Nguyen K, Devidas M, Cheng S, La M, Raetz E, Carroll W et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study. Leukemia 2008; 22: 2142-2150.
5. Tavernier E, Boiron J, Huguet F, Bradstock K, Vey N, Kovacsovics T et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907-1914.
6. Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF et al. Potentiating effects of RAD001 (everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009; 113: 3297-3306.
7. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400-1406.
8. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009; 5: 727-728.
9. Grunwald V, de graffenried L, Russel D, Friedrichs W, Ray R, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-6145.
10. Teachey D, Sheen C, Hall J, Ryan T, Brown V, Fish J et al. mTOR inhibitors are synergistic with methotrexate: An effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020-2023.
11. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G(1) and G(2) cell-cycle arrest following microtubule de polymerization in human breast cancer cells. J Clin Invest 2002; 110: 91-99.
12. Hawkins DS, de mers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996; 56: 892-898.
13. Harper JW, Elledge SJ. The DNA damage response: Ten years after. Mol Cell 2007; 28: 739-745.
14. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006; 134: 475-484.
15. Mabuchi S, Altomare D, Cheung M, Zhang L, Poulikakos P, Hensley H et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatininduced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261-4270.
16. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 2011; 96: 69-77.
17. Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol 2010; 11: 208-219.
18. Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT. Rapamycininduced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993; 268: 3734-3738.
19. Law M, Forrester E, Chytil A, Corsino P, Green G, Davis B et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 2006; 66: 1070-1080.
20. Haritunians T, Mori A, O?Kelly J, Luong Q, Giles F, Koeffler H. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007; 21: 333-339.
21. Gao N, Zhang Z, Jiang B, Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003; 310: 1124-1132.
22. Gao N, Flynn D, Zhang Z, Zhong X, Walker V, Liu K et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004; 287: C281-C291.
23. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis G, Medeiros L. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169: 2171-2180.
24. Segurado M, Tercero JA. The S-phase checkpoint: Targeting the replication fork. Biol Cell 2009; 101: 617-627.
25. Petersen J, Nurse P. TOR signalling regulates mitotic commitment through the stress MAP kinase pathway and the Polo and Cdc2 kinases. Nat Cell Biol 2007; 9: 1263-1272.
26. Wu MY, Cully M, Andersen D, Leevers SJ. Insulin de lays the progression of Drosophila cells through G2/M by activating the dTOR/dRaptor complex. EMBO J 2007; 26: 371-379.
27. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U et al. Optimized anti-tumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Blood 2011; 118: 6123-6131.
28. Ito D, Matsumoto T. Molecular mechanisms and function of the spindle checkpoint, a guardian of the chromosome stability. Adv Exp Med Biol 2010; 676: 15-26.
29. Portugal J, Mansilla S, Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm de s 2010; 16: 69-78.
30. Peterson RT, de sai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA 1999; 96: 4438-4442.
31. Peng A, Maller JL. Serine/threonine phosphatases in the DNA damage response and cancer. Oncogene 2010; 29: 5977-5988.
32. Su WC, Liu WL, Cheng CW, Chou YB, Hung KH, Huang WH et al. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009; 583: 2793-2798.
33. Song J, Salek-Ardakani S, So T, Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 2007; 8: 64-73.
34. Yang C, Tang X, Guo X, Niikura Y, Kitagawa K, Cui K et al. Aurora-B mediated ATM serine 1403 phosphorylation is required for mitotic ATM activation and the spindle checkpoint. Mol Cell 2011; 44: 597-608.
35. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004; 23: 4362-4370.
36. Bendall LJ, Kortlepel K, Gottlieb DJ. Human acute myeloid leukemia cells bind to bone marrow stroma via a combination of beta 1 and beta 2 integrin mechanisms. Blood 1993; 82: 3125-3132.
37. Bradstock K, Bianchi A, Makrynikola V, Filshie R, Gottlieb D. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia 1996; 10: 813-820.
38. Juarez J, Bradstock K, Gottlieb D, Bendall L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-1300.